Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23938174 | 0.75 | LMNA (0.39) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL5039833 | 0.71 | — | — | |
| SCHEMBL20731029 | 0.69 | TLR8 (0.38) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL5508010 | 0.68 | TLR8 (0.51) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL23938023 | 0.68 | GAA (0.41) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL1620567 | 0.67 | NPC1 (0.48) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL23938070 | 0.67 | TLR8 (0.36) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL24162039 | 0.66 | GAA (0.39) | TLR8TLR7NPC1GAAMAPK1 | |
| SCHEMBL23938015 | 0.66 | USP2 (0.33) | GAA | |
| SCHEMBL14684249 | 0.63 | RAB9A (0.56) | TLR8TLR7NPC1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | TLR8 3437/4885TLR7 4364/4885NPC1 3743/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | TLR8 3437/4885TLR7 4364/4885NPC1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.